Clocortolone Pivalate

also known as Clocortolone 21-pivalate · Cloderm · Cloderm Cream · SH 863

Small molecule targets NR3C1 via activation

Developed for: psoriasis
Investigated by: Promius Pharma, LLC · Sun Pharmaceutical Industries, Inc. · WAYCro

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	US (FDA)	CLODERM	—	1977-08-22	fda.gov ↗

Trials 2

today

US approved 1977

NCT04358770 · Ph 1 NCT01714544 · Ph 4

1977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 11 trial
Phase 1	NCT04358770	Mar → Apr 2018	—	Sun Pharmaceutical Industries, Inc.	Completed	No outcome recorded
Phase 41 trial
Phase 4	NCT01714544	Oct 2012 → Mar 2013	psoriasis	Promius Pharma, LLC	Completed	No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	Clocortolone Pivalate	“Cloderm® Cream (Clocortolone Pivalate, 0.1%)” NCT01714544 ↗ 1 NCT04358770 ↗
Known as	Clocortolone 21-pivalate	ChEMBL registry synonym — accepted as the source's own label CHEMBL1200975 ↗
Known as	Cloderm	“Cloderm® Cream (Clocortolone Pivalate, 0.1%)” NCT01714544 ↗
Known as	Cloderm Cream	“Cloderm® Cream (Clocortolone Pivalate, 0.1%)” NCT01714544 ↗
Known as	SH 863	ChEMBL registry synonym — accepted as the source's own label CHEMBL1200975 ↗
Action	Activate	“Glucocorticoid receptor agonist” CHEMBL1200975 ↗
Modality	Small molecule	— CHEMBL1200975 ↗
Route	Topical	“topical treatment” NCT01714544 ↗
Target	NR3C1	“Glucocorticoid receptor agonist” CHEMBL1200975 ↗